T3D Therapeutics, Inc. Receives FDA IND Approval to Begin Phase 2 Clinical Study of T3D-959 in Alzheimer’s Patients

T3D Therapeutics, Inc., a Research Triangle Park, NC- based developer of Alzheimer’s disease therapies, announced that the Division of Neurology Products of the U.S. Food and Drug Administration has approved the company’s Investigational New Drug (IND) application to begin a Phase 2a clinical study of T3D–959, the company’s lead product candidate, in patients with mild-to-moderate Alzheimer’s disease.

Commenting on the approval, T3D Therapeutics’ CEO John Didsbury said, “We are pleased to have received FDA clearance to begin our Phase 2a clinical study and look forward to initiating the study. This is a significant milestone for our company.”

Read the full press release here.